The remarkable antitumor response elicited by immune checkpoint inhibitors, such as programmed cell death protein 1 (PD-1) blockade, against metastatic cancers of different histologies has generated an unprecedented wave of interest in identifying factors that liberate tumor-specific T cells to exert their effector functions against tumor cells (4–6). Here, PDCD1 is linked to metastatic malignant neoplasm.